<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704106</url>
  </required_header>
  <id_info>
    <org_study_id>PHF008</org_study_id>
    <nct_id>NCT00704106</nct_id>
  </id_info>
  <brief_title>Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders</brief_title>
  <acronym>ADVPR</acronym>
  <official_title>HBV Viral Suppression by Entecavir in Adefovir Partial Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacific Health Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pacific Health Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a largely retrospective study with short-term prospective follow-up in a subgroup
      of patients who have not yet been treated with 48 weeks of entecavir following partial
      response to adefovir. The aim of the study is to describe sequential virologic response to
      adefovir and entecavir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amendment was made, and approved by WIRB in January 2009, to this protocol: We propose a
      largely retrospective study with short-term prospective follow-up in a subgroup of patients
      who have not yet been treated with 96 weeks of entecavir following adefovir treatment. The
      aim of the study is to describe sequential virologic response to adefovir and entecavir.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>HBV DNA PCR after 12 weeks of entecavir from the time of medication switching: percent of patients with &lt;2log drop in HBV DNA and percent of patients with complete viral suppression during adefovir versus during entecavir.</measure>
    <time_frame>48 weeks or after</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV DNA PCR after 24 weeks of entecavir from the time of medication switching.</measure>
    <time_frame>48 weeks or after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA PCR after 48 weeks of entecavir from the time of medication switching.</measure>
    <time_frame>48 weeks or after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BR and CR at 24 and 48 weeks of therapy with entecavir.</measure>
    <time_frame>48 weeks or after.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BR and CR for longer duration of therapy if available.</measure>
    <time_frame>48 weeks or after.</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Persistent viremia after 48 weeks or longer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>&lt;2 log IU/mL drop from initial HBVDNA after 12 weeks of adefovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Patients who responded to adefovir and were switched to entecavir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Patients with 160 copies/mL (100 IU/mL) or higher at the time of medication switch.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>0.5 or 1 mg dose qd</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Age 18 years or older

          -  All genders and ethnicity

          -  Positive HBsAg

          -  HBeAg positive and negative

          -  Pretreatment HBV DNA of 10,000 copies/mL or higher (for purposes of this study, both
             copies and equivalent IU measurements will be recorded and analyzed)

          -  Patients who are switched to, or prescribed, entecavir after treatment with adefovir
             for at least 12 weeks by the providing physician

          -  Patients with and without prior lamivudine exposure will be enrolled but enrollment of
             lamivudine experienced cases will be limited to no more than 30 patients total
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        KEY INCLUSION CRITERIA:

          -  Age 18 years or older

          -  All genders and ethnicity

          -  Positive HBsAg

          -  HBeAg positive and negative

          -  Pretreatment HBV DNA of 10,000 copies/mL or higher (for purposes of this study, both
             copies and equivalent IU measurements will be recorded and analyzed)

          -  Patients who are switched to, or prescribed, entecavir after treatment with adefovir
             for at least 12 weeks by the providing physician.

          -  Patients with and without prior lamivudine exposure will be enrolled but enrollment of
             lamivudine experienced cases will be limited to no more than 30 patients total

        KEY EXCLUSION CRITERIA:

          -  Patients who refused to consent to the study

          -  Patients younger than 18

          -  Vulnerable subjects such as pregnant women, prisoners, employees, patients with
             significant cognitive deficits.

          -  Patients with prior exposure to another nucleoside for more than 2 weeks. Those with
             prior exposure to lamivudine will be enrolled under conditions detailed above.

          -  HIV co-infection

          -  HCV co-infection

          -  HDV co-infection

          -  Recipients of solid organ transplantation

          -  Patients who receive high-dose steroid (60 mg/d or higher and for longer than 10 days)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huy N Trinh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Health Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mindie H Nguyen, M.D., M.A.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Health Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jose Gastroenterology</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jose Gastroenterology</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Village Medical Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Gastroenterology Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Health Associates of Texas</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25 Suppl 1:3-8. Review.</citation>
    <PMID>16103976</PMID>
  </reference>
  <reference>
    <citation>Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan 4;295(1):65-73.</citation>
    <PMID>16391218</PMID>
  </reference>
  <reference>
    <citation>Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006 Mar;130(3):678-86.</citation>
    <PMID>16530509</PMID>
  </reference>
  <reference>
    <citation>Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31.</citation>
    <PMID>15470215</PMID>
  </reference>
  <reference>
    <citation>Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007 Feb;45(2):507-39. Erratum in: Hepatology. 2007 Jun;45(6):1347.</citation>
    <PMID>17256718</PMID>
  </reference>
  <reference>
    <citation>Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006 Aug;4(8):936-62. Epub 2006 Jul 14. Review.</citation>
    <PMID>16844425</PMID>
  </reference>
  <reference>
    <citation>Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2004 Dec;2(6):853-71. Review.</citation>
    <PMID>15566330</PMID>
  </reference>
  <reference>
    <citation>Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA; 018 Study Group. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007 Dec 4;147(11):745-54. Epub 2007 Oct 1.</citation>
    <PMID>17909201</PMID>
  </reference>
  <reference>
    <citation>Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, Zoulim F. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007 Aug;5(8):890-7. Epub 2007 Jul 13. Review.</citation>
    <PMID>17632041</PMID>
  </reference>
  <reference>
    <citation>Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology. 2006 Dec;44(6):1656-65.</citation>
    <PMID>17133475</PMID>
  </reference>
  <reference>
    <citation>Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009 May;49(5):1503-14. doi: 10.1002/hep.22841.</citation>
    <PMID>19280622</PMID>
  </reference>
  <reference>
    <citation>Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005 Jun 30;352(26):2673-81.</citation>
    <PMID>15987916</PMID>
  </reference>
  <reference>
    <citation>Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006 Dec;131(6):1743-51. Epub 2006 Sep 20.</citation>
    <PMID>17087951</PMID>
  </reference>
  <reference>
    <citation>Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology. 2009 Sep;50(3):727-34. doi: 10.1002/hep.23044.</citation>
    <PMID>19517525</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2008</study_first_posted>
  <last_update_submitted>May 8, 2012</last_update_submitted>
  <last_update_submitted_qc>May 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

